News | August 09, 2023
Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The new Biolys provides higher concentration of L-lysine
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
Subscribe To Our Newsletter & Stay Updated
